We proudly present our first installation of our remote controlled manipulator in Belgium! We wish Dr. P. De Visschere and his team at the University Hospital in Gent good luck with the system and their research to improve prostate cancer diagnostics.
Soteria started the new year with the first installation in Finland. We thank drs. Merja Raade and her team of the Docrates Cancer Center (DCC) in Helsinki for the welcome stay during our training and installation of a new RCM system. DCC is now able to offer in-bore MRI guided prostate biopsies to get the best cancer diagnosis for their patients.
Soteria Medical had a very busy and productive year 2018, with success in several areas. We significantly expanded our installed base in Europe and have installed the first RCM in Asia. The clinical data from our users show very positive results and consistent cancer detection rates across all different countries and centers. This combined with the short and decreased procedure times in all these settings shows the successful integration of the RCM in our users’ clinical routines. Dr. Petralia and his group from Instituto Europeo di Oncologia in Milan, Italy presented their clinical results with the RCM at this year’s RSNA showing not only a decrease in procedure time but also an increase in positive core length in the first two biopsy samples – proving the expected increase in accuracy of robot-assisted MR-guided bx.
2018 was also a very good year in the fight against Prostate Cancer in general: A couple of major (multicenter) studies (4M – Euro. Uro., PRECISION – N. Eng J Med, MRI-first - Lancet and Costa et al. Eur. Uro.) have shown that we can reduce the amount of biopsies in men by 27- 49% in using MRI diagnostics followed by targeted biopsies. Less insignificant cancers are found which will result in less unnecessary treatment of men. While up to 12% more (small) significant cancers can be detected. We are looking forward what 2019 will bring!
Soteria Medical is working on many exciting product developments in the field of MR-guided interventions with a focus on prostate cancer diagnosis and treatment. We expect to release the next products in 2019, while continuing to work with our clinical and industrial partners across the globe.
We are looking forward to another very busy and successful year in 2019.